Director gifts 80,000 Phathom Pharmaceuticals shares

Phathom Pharmaceuticals director Asit Parikh reported gifting 80,000 shares of Common Stock.

Accepted by SEC EDGAR 03/11/2026 - 06:54 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Phathom Pharmaceuticals director Asit Parikh reported gifting 80,000 shares of Common Stock. On March 10, 2026, he made two bona fide gift transfers of 40,000 shares each, with no cash consideration.

After these gifts, Parikh directly holds 10,500 shares and indirectly holds 120,500 shares through a trust for the benefit of his spouse, for which he serves as trustee. These are non-market, charitable-style transfers rather than open-market sales.

Insider Trade Summary

80,000 shares gifted

Gift 2 txns

Insider Parikh Asit

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	40,000	$0.00	$0.00
Gift	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 10,500 shares (Direct); Common Stock — 120,500 shares (Indirect, by Trust)

Holdings Before and After: Common Stock, 50,500 to 10,500 shares (Direct); Common Stock, 160,500 to 120,500 shares (Indirect, by Trust)

Footnotes (1)

1. F1. Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Phathom Pharmaceuticals (PHAT) disclose?

Phathom Pharmaceuticals director Asit Parikh disclosed two bona fide gifts totaling 80,000 shares of Common Stock. These were non-cash transfers made on March 10, 2026, rather than open-market purchases or sales, and therefore carry limited direct market signaling value.

How many Phathom Pharmaceuticals (PHAT) shares did Asit Parikh gift?

Asit Parikh gifted a total of 80,000 shares of Phathom Pharmaceuticals Common Stock. The Form 4 shows two separate bona fide gift transactions of 40,000 shares each, both dated March 10, 2026, with a reported price of $0.00 per share.

What are Asit Parikh’s holdings in Phathom Pharmaceuticals (PHAT) after the gifts?

Following the reported gifts, Asit Parikh holds 10,500 shares directly and 120,500 shares indirectly through a trust. The indirect holdings are reported as owned “by Trust,” reflecting shares held for the benefit of his spouse with Parikh serving as trustee.

Were the Phathom Pharmaceuticals (PHAT) insider transactions market sales?

No, the transactions were bona fide gifts, not market sales. The Form 4 uses transaction code G, with a price of $0.00 per share, indicating transfers for no consideration rather than open-market selling activity that would generate cash proceeds.

Who benefits from the trust holding Phathom Pharmaceuticals (PHAT) shares?

The filing notes that shares were transferred for no consideration to a trust for the benefit of the reporting person’s spouse. Asit Parikh serves as trustee, and the Form 4 reports these shares as indirectly owned, described with the nature of ownership “by Trust.”

How many gift transactions did Phathom Pharmaceuticals (PHAT) report for Asit Parikh?

The summary shows two gift transactions for Asit Parikh. Both are coded as bona fide gifts (code G) of Common Stock, each involving 40,000 shares. Together they account for 80,000 shares disposed of as gifts on March 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Asit

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		G		40,000	D	$0	10,500	D
Common Stock	03/10/2026		G		40,000	A	$0	120,500(1)	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.

	/s/ Anne Marie Cook, Attorney-in-Fact for Asit Parikh	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.